Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study

Basit Öğe Kaydı
dc.authorid0000-0003-2184-634X
dc.authorid0000-0001-7934-7039
dc.contributor.authorŞenocak Taşçı, Elif
dc.contributor.authorKutlu, Yasin
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorMutlu, Arda Ulaş
dc.contributor.authorGündoğdu, Yasemin
dc.contributor.authorSeyyar, Mustafa
dc.contributor.authorŞahin, Elif
dc.contributor.authorÇabuk, Devrim
dc.contributor.authorMajidova, Nargiz
dc.contributor.authorUğurlu, İrem
dc.contributor.authorDemirci, Ayşe
dc.contributor.authorAydın, Dinçer
dc.contributor.authorÇavdar, Eyyüp
dc.contributor.authorBayram, Selami
dc.contributor.authorYıldırım, Nilgün
dc.contributor.authorKarataş, Fatih
dc.contributor.authorKarakurt Eryılmaz, Melek
dc.contributor.authorÇağlayan, Dilek
dc.contributor.authorMenekşe, Serkan
dc.contributor.authorKut, Engin
dc.contributor.authorArak, Hacı
dc.contributor.authorKeser, Murat
dc.contributor.authorSunar, Veli
dc.contributor.authorPerkin, Perihan
dc.contributor.authorŞakalar, Teoman
dc.contributor.authorOyan, Başak
dc.contributor.authorSönmez, Özlem
dc.contributor.authorÖzer, Leyla
dc.contributor.authorYıldız, İbrahim
dc.date.accessioned2024-05-14T08:20:34Z
dc.date.available2024-05-14T08:20:34Z
dc.date.issued2024
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractBackground: Triple negative breast cancer (TNBC) is characterized by high rates of recurrence, especially in patients with residual disease after neoadjuvant chemotherapy (NAC). Capecitabine is being used as standard adjuvant treatment in residual TNBC. We aimed to investigate the real-life data regarding the efficacy of capecitabine in residual TNBC. Design and methods: In this retrospective multicenter study, TNBC patients with residual disease were evaluated. Patients, who received standard anthracycline and taxane-based NAC and adjuvant capecitabine were eligible. Overall survival (OS), disease free survival (DFS) and toxicity were analyzed. Results: 170 TNBC patients with residual disease were included. Of these, 62.9% were premenopausal. At the time of analysis, the recurrence rate was 30% and death rate was 18%. The 3-year DFS and OS were 66% and 74%, respectively. In patients treated with adjuvant capecitabine, residual node positive disease stood out as an independent predictor of DFS (p = 0.024) and OS (p = 0.032). Undergoing mastectomy and the presence of T2 residual tumor was independent predictors of DFS (p = 0.016) and OS (p = 0.006), respectively. Conclusion: The efficacy of capecitabine was found lower compared to previous studies. Selected patients may have further benefit from addition of capecitabine. The toxicity associated with capecitabine was found lower than anticipated.
dc.identifier.citationŞenocak Taşçı, E., Kutlu, Y., Ölmez, Ö. F., Mutlu, A. U., Gündoğdu, Y., Seyyar, M. ... Yıldız, İ. (2024). Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study. Expert Opinion on Pharmacotherapy, (25)4, 477-484. http://dx.doi.org/10.1080/14656566.2024.2337261
dc.identifier.doi10.1080/14656566.2024.2337261
dc.identifier.endpage484
dc.identifier.issn1465-6566
dc.identifier.issn1744-7666
dc.identifier.issue4
dc.identifier.pmid38568074
dc.identifier.scopus2-s2.0-85189873288
dc.identifier.scopusqualityQ2
dc.identifier.startpage477
dc.identifier.urihttp://dx.doi.org/10.1080/14656566.2024.2337261
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12449
dc.identifier.volume25
dc.identifier.wos001196635300001en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKutlu, Yasin
dc.institutionauthorÖlmez, Ömer Fatih
dc.language.isoen
dc.relation.ispartofExpert Opinion on Pharmacotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBreast Cancer
dc.subjectCapecitabine
dc.subjectResidual Tumor
dc.subjectToxicity
dc.subjectTriple Negative
dc.titleEfficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu